Lidocaina Cloridrato Monico (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing the rapid influx of sodium ions needed for depolarisation. This reversible blockade stops the propagation of action potentials, producing loss of sensation in the targeted area and stabilising abnormal cardiac electrical activity.

The appropriate dose is determined by the prescribing clinician based on the specific indication, patient characteristics, and clinical setting. Dosage regimens are not standardized in public literature and must follow the prescriber’s order and local regulatory guidance.

Safety data for lidocaine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for many short‑procedures. Compared with ester‑type agents such as procaine, lidocaine has a lower risk of allergic reactions and a more predictable pharmacokinetic profile.

Lidocaina Cloridrato Monico should be stored at ambient temperature, preferably below 25 °C, in its original container. Protect the solution from light, moisture and extreme temperatures to maintain stability and potency.

The product is supplied as a sterile injectable solution for intravenous administration. It is administered by a qualified healthcare professional, typically as a slow infusion or controlled bolus, according to the prescriber’s instructions and institutional protocols.

Serious adverse events include anaphylactic reactions, severe cardiac conduction disturbances such as bradycardia or heart block, and central nervous system toxicity that may present as seizures, confusion or loss of consciousness. Immediate medical attention is required if these occur.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with certain cardiac conduction disorders should avoid this medication unless a risk‑benefit assessment justifies its use.